Zealand Pharma

Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zealand Pharma provides business update related to current COVID-19 situation

Correction: Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Transactions in  Zealand Pharma  shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Total number of shares and voting rights in Zealand Pharma at March 31, 2020

Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal® Rescue Pen for treatment of severe hypoglycemia

Zealand Pharma completes subscription of New Ordinary Shares and registration of capital increase

Zealand Pharma announces positive topline results from Phase 2 trial with dasiglucagon in individuals who have undergone bariatric surgery

Zealand Pharma announces private placement and directed issue of new shares with expected gross proceeds of DKK 137,236,000

Annual General Meeting of Zealand Pharma A/S: Measures in consequence of COVID-19

Zealand Pharma regains worldwide rights to Amylin analog program from Boehringer Ingelheim

Zealand Pharma  increases  its share capital as a consequence of exercise of employee warrants

Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q4 2019 Results - Earnings Call Transcript

Zealand Pharma convenes its Annual General Meeting 2020

Zealand Pharma advances pipeline and maintains strong cash position: full year results for 2019

Zealand Pharma to attend 9th Annual SVB Leerink Global Healthcare Conference

Zealand Pharma  major shareholder announcement: Wellington Management Group LLP

Zealand Pharma announces bid to acquire Valeritas

Zealand Pharma Flying Under Everyone's Radar

Total number of shares and voting rights in Zealand Pharma at December 31, 2019

Transactions in Zealand Pharma shares (ZEAL) and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma increases  its share capital as a consequence of exercise of employee warrants

Zealand Pharma  announces amendments to its Articles of Association following the granting of warrants

Financial calendar for Zealand Pharma in 2020

Zealand Pharma partner Beta Bionics receives FDA Breakthrough Device Designation for the iLet™ Bionic Pancreas System

Zealand (ZEAL) announces initiation of the second phase III study to evaluate dasiglucagon in pediatric patients with congenital hyperinsulinism.

Zealand Initiates Second Late-Stage CHI Study on Dasiglucagon

News for Zealand Pharma Stock (ZEAL)